Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $629.19 million. The enterprise value is $696.09 million.
Important Dates
The last earnings date was Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 93.21 million shares outstanding. The number of shares has increased by 2.77% in one year.
| Current Share Class | 93.21M |
| Shares Outstanding | 93.21M |
| Shares Change (YoY) | +2.77% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 2.64% |
| Owned by Institutions (%) | 92.50% |
| Float | 85.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 114.13 |
| PS Ratio | 0.72 |
| Forward PS | 0.72 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 3.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.57.
| Current Ratio | 2.33 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.07 |
Financial Efficiency
Return on equity (ROE) is -72.52% and return on invested capital (ROIC) is -7.03%.
| Return on Equity (ROE) | -72.52% |
| Return on Assets (ROA) | -5.67% |
| Return on Invested Capital (ROIC) | -7.03% |
| Return on Capital Employed (ROCE) | -14.15% |
| Revenue Per Employee | $305,667 |
| Profits Per Employee | -$148,333 |
| Employee Count | 2,700 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 8.46 |
Taxes
| Income Tax | -24.80M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.14% in the last 52 weeks. The beta is 1.81, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.81 |
| 52-Week Price Change | -62.14% |
| 50-Day Moving Average | 7.50 |
| 200-Day Moving Average | 7.53 |
| Relative Strength Index (RSI) | 37.23 |
| Average Volume (20 Days) | 985,577 |
Short Selling Information
The latest short interest is 7.76 million, so 8.33% of the outstanding shares have been sold short.
| Short Interest | 7.76M |
| Short Previous Month | 7.79M |
| Short % of Shares Out | 8.33% |
| Short % of Float | 9.07% |
| Short Ratio (days to cover) | 5.95 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $825.30 million and -$400.50 million in losses. Loss per share was -$4.36.
| Revenue | 825.30M |
| Gross Profit | 580.70M |
| Operating Income | -82.10M |
| Pretax Income | -425.30M |
| Net Income | -400.50M |
| EBITDA | -26.20M |
| EBIT | -82.10M |
| Loss Per Share | -$4.36 |
Full Income StatementBalance Sheet
The company has $145.40 million in cash and $212.30 million in debt, giving a net cash position of -$66.90 million or -$0.72 per share.
| Cash & Cash Equivalents | 145.40M |
| Total Debt | 212.30M |
| Net Cash | -66.90M |
| Net Cash Per Share | -$0.72 |
| Equity (Book Value) | 372.80M |
| Book Value Per Share | 4.00 |
| Working Capital | 196.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.20 million and capital expenditures -$14.50 million, giving a free cash flow of -$16.70 million.
| Operating Cash Flow | -2.20M |
| Capital Expenditures | -14.50M |
| Free Cash Flow | -16.70M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
Gross margin is 70.36%, with operating and profit margins of -9.95% and -48.53%.
| Gross Margin | 70.36% |
| Operating Margin | -9.95% |
| Pretax Margin | -51.53% |
| Profit Margin | -48.53% |
| EBITDA Margin | -3.17% |
| EBIT Margin | -9.95% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.77% |
| Shareholder Yield | -2.77% |
| Earnings Yield | -63.65% |
| FCF Yield | -2.65% |
Dividend DetailsAnalyst Forecast
The average price target for Myriad Genetics is $13.27, which is 96.00% higher than the current price. The consensus rating is "Hold".
| Price Target | $13.27 |
| Price Target Difference | 96.00% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 3.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of 0.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.58 |
| Piotroski F-Score | 4 |
